Merck Invests More Than € 300 Million in New Life Science Research Center in Germany

Research center to accelerate biopharmaceutical product development

26-Apr-2024 - Merck, a leading science and technology company, is investing more than €300 million in a new research center at its global headquarters in Darmstadt, Germany. In the Advanced Research Center, the Life Science business sector will research solutions for manufacturing antibodies, mRNA ...

Merck Invests € 23 Million to Expand Cell Culture Media Production in Kansas, USA

Boosts capabilities with additional 9,100 sq m2 of manufacturing and redesigned lab space

13-Jul-2023 - Merck, announced the expansion of its facility in Lenexa, Kansas, USA adding 9,100 sq m2 of lab space and production capability to manufacture cell culture media. “The Lenexa expansion reflects our commitment to meeting the dynamic needs of our customers worldwide and delivering on our growth ...

Merck Invests € 250 Million in Production Value Chain in China

04-Nov-2016 - Merck inaugurated its € 170 million Nantong pharmaceutical plant, which is dedicated to producing high-quality pharmaceuticals on China’s Essential Drug List. At the inauguration ceremony, Merck also announced a further investment of around € 80 million in a Life Science Center near the Nantong ...

Merck Acquires Cell Culture Media Specialist Biochrom AG

Acquisition rounds out Merck Millipore’s portfolio of media and buffers used in biopharmaceutical production

23-Aug-2012 - Merck announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany. The company, with approximately 60 employees and sales of approximately € 13 million in 2011, specializes in the production and marketing of cell-culture media and buffer solutions. ...

Plasticell and EMD Millipore complete licensing deal to distribute fully defined, xeno-free mesenchymal stem cell differentiation media

16-Aug-2012 - Plasticell has licensed EMD Millipore to distribute a superior, single-application osteogenic medium discovered using the combinatorial screening system, CombiCult®.The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations. Under the ...

Merck KGaA Acquires Supplier to Biopharma Industry in China

11-Jan-2011 - Merck KGaA announced that it has acquired 100% of the share capital of Beijing Skywing Technology Co., Ltd., a supplier of cell-culture media products, related technical services and bioreactors for the Chinese biopharmaceutical industry. The company is headquartered in the Changping district of ...